A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

NCT07739758 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

442

Enrollment

INDUSTRY

Sponsor class

Conditions

SCLC, Extensive Stage

Interventions

DRUG: YL201
DRUG: Serplulimab
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.

Collaborators

[object Object]